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Abstract
Background: Cardiac power output (CPO), derived from the product of cardiac output and mean aortic pressure, is
an important yet underexploited parameter for hemodynamic monitoring of critically ill patients in the intensive-
care unit (ICU). The conductance catheter-derived pressure-volume loop area reflects left ventricular stroke work (LV
SW). Dividing LV SW by time, a measure of LV SW min− 1 is obtained sharing the same unit as CPO (W). We aimed
to validate CPO as a marker of LV SW min− 1 under various inotropic states.
Methods: We retrospectively analysed data obtained from experimental studies of the hemodynamic impact of
mild hypothermia and hyperthermia on acute heart failure. Fifty-nine anaesthetized and mechanically ventilated
closed-chest Landrace pigs (68 ± 1 kg) were instrumented with Swan-Ganz and LV pressure-volume catheters. Data
were obtained at body temperatures of 33.0 °C, 38.0 °C and 40.5 °C; before and after: resuscitation, myocardial
infarction, endotoxemia, sevoflurane-induced myocardial depression and beta-adrenergic stimulation. We plotted
LVSW min− 1 against CPO by linear regression analysis, as well as against the following classical indices of LV
function and work: LV ejection fraction (LV EF), rate-pressure product (RPP), triple product (TP), LV maximum
pressure (LVPmax) and maximal rate of rise of LVP (LV dP/dtmax).
Results: CPO showed the best correlation with LV SW min− 1 (r2 = 0.89; p < 0.05) while LV EF did not correlate at all
(r2 = 0.01; p = 0.259). Further parameters correlated moderately with LV SW min− 1 (LVPmax r
2 = 0.47, RPP r2 = 0.67;
and TP r2 = 0.54). LV dP/dtmax correlated worst with LV SW min
− 1 (r2 = 0.28).
Conclusion: CPO reflects external cardiac work over a wide range of inotropic states. These data further support
the use of CPO to monitor inotropic interventions in the ICU.
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Background
Benefits of acquiring hemodynamic information by pul-
monary artery catheterization (PAC) in conditions of crit-
ical illness are controversial. Following several neutral
studies arguing against the survival benefit of hemodynamic
monitoring by PAC in different populations of critically ill
patients [1–9], the use of PAC is not recommended as a
diagnostic routine anymore [10, 11]. One possible explan-
ation for the neutral effects of PAC is the lack of clear
hemodynamic goals to guide evidence-based therapies [4].
A promising parameter for hemodynamic monitoring of
critically ill patients is cardiac power output (CPO), which
is assessed as the product of cardiac output (CO) and mean
aortic pressure (MAP), divided by a constant of 451 [12].
Being the product of flow and pressure, CPO describes the
function of the heart as a mechanical pump [13], represent-
ing the rate of external work done by the left ventricle. In
addition, CPO has been shown to be the strongest inde-
pendent predictor of intrahospital mortality in patients with
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cardiogenic shock [12] and to strongly correlate with out-
come in chronic heart failure patients [14]. CPO might
therefore be a relevant yet underexplored way to describe a
patient’s hemodynamic state in the intensive care unit
(ICU) setting [12].
The most comprehensive way to describe ventricular per-
formance is pressure-volume analysis. Over the last decades,
it became the gold standard to quantify cardiac function
in vivo by providing measures that are reasonably load-
independent, such as the end-systolic and end-diastolic
pressure-volume relationships [15–17]. Pressure-volume
analysis not only offers load-independent information, but it
allows to quantify ventricular energetics and describes the
interaction between heart and vasculature [18–20]. The area
of the pressure-volume loop reflects the external work of
the heart, also called left ventricular stroke work (LV SW).
When LV SW is divided by time, a measure of LV SW per
minute is obtained that shares the same unit as CPO
(Watts). The correlation between CPO, as measured by
PAC and invasive arterial pressure, and LV SW min− 1 mea-
sured via the invasive gold-standard (conductance method)
has never been tested so far. The aim of the study was there-
fore to validate CPO as a marker of the actual LV SW min−
1 over a wide range of inotropic states. We therefore con-
ducted a retrospective data analysis of previous animal stud-
ies from our group, in which we investigated the
hemodynamic impact of mild hypothermia (MH, 33.0 °C)
and hyperthermia (HT, 40.5 °C) by pressure-volume analysis
in several porcine models of acute heart failure representa-
tive for patients in the ICU [21–24]. LV SW min− 1 was fur-
ther compared with clinically established indices to describe
LV function and work, such as left ventricular ejection frac-
tion (LV EF), left ventricular maximum pressure (LVPmax),
maximum rate of rise of left ventricular pressure (LV dP/
dtmax), rate-pressure product [RPP = heart rate (HR) x
LVPmax] and triple product (TP =RPP x LV dP/dtmax).
Methods
The experimental protocols were approved by the local
bioethics committee of Vienna, Austria (Austrian
Committee for Animal Trials, in German “Tierversuchs-
kommission”, BMWF-66.010/0091-II/3b/2013, BMWF-
66.010/0033-II/10b/2008, BMWF-66.010/0103-II/10b/
2009, BMWF-66.010/0108-II/3b/2010), and conform to
the “European Convention for the Protection of Verte-
brate Animals used for Experimental and other Scientific
Purposes” (Council of Europe No 123, Strasbourg 1985).
Landrace pigs were ordered from Heinz Stelzl,
Großklein, Austria, and were delivered to the Institute
for Biomedical Research of the Medical University of
Graz (Roseggerweg 48, 8036 Graz, Austria). The experi-
ments were performed either at the Section for Surgical
Research, Department of Experimental Surgery (Auen-
bruggerplatz 15, 8036 Graz, Austria) or at the
abovementioned Institute for Biomedical Research of the
Medical University of Graz.
Experimental setup
The experimental setup has been described before [25].
Briefly, Landrace pigs (n= 59, 68 ± 1 kg) were fasted over-
night with free access to water and sedated with 0.25–0.5
mg kg− 1 midazolam (Midazolam „ERWO “5mg/ml- am-
poules, ERWO Pharma GmbH, Brunn am Gebirge, Austria)
and 10–20mg kg− 1 ketamine (Ketasol 100mg/ml, aniMedica
GmbH, Senden-Bösensell, Germany). The animals were
intubated and anaesthesia was continued with 1.0–2.0 Vol%
sevoflurane (Sevorane®, Abbott GmbH, Vienna, Austria), 30–
35 μg kg− 1 h− 1 fentanyl (Fentanyl-Janssen™, 0.1mg ampoules,
Janssen-Cilag Pharma, Vienna, Austria), 1–1.25mg kg− 1 h− 1
midazolam, 3mg kg− 1 h− 1 ketamine and 0.2mg kg− 1 h− 1
pancuronium (Pancouronium bromide 2mg/ml ampoules,
Ratiopharm GmbH, Ulm, Germany). Pigs were ventilated
(Julian, Draeger, Vienna, Austria) with an FiO2 (Fraction of
inspired oxygen) of 0.5, an I: E-ratio of 1:1.5, the positive
end-expiratory pressure was set at 5mmHg and a tidal vol-
ume (VT) of 10ml kg− 1. The respiratory rate was adjusted
constantly to maintain an end-expiratory carbon dioxide par-
tial pressure between 35 and 45mmHg. Under fluoroscopic
guidance, all animals were instrumented with a Swan-Ganz
catheter (Edwards Lifesciences CCO connected to Vigilance
I, Edwards Lifesciences, Irvine, CA, USA), and an LV con-
ductance catheter (5F, 12 electrodes, 7mm spacing, MPVS
Ultra, Millar Instruments, Houston, Texas, USA). A 14-F
sheath was introduced into the left femoral vein, and an
intravascular cooling catheter connected to a cooling unit
(Accutrol™ Catheter 14F and InnerCool RTx Endovascular
System, Philips Healthcare, Vienna, Austria) was positioned
with the tip at the level of the diaphragm in the inferior caval
vein. The body core temperature was measured at the tip of
the Swan-Ganz-catheter. After instrumentation, the animals
were allowed to stabilize for 30–60min.
Experimental protocols
The experimental protocols are summarized in Fig. 1
and have been described in detail before [21–24].
Steady-state hemodynamics were obtained and averaged
over three respiratory cycles. At each time point, volumet-
ric conductance data were calibrated by measuring cardiac
output (slope factor a) and hypertonic (10%) saline infu-
sion (parallel volume) as described earlier [26, 27]. At the
end of each experimental protocol anaesthetised and un-
conscious animals were euthanized by an injection of an
80mmol potassium chloride bolus.
Group 1 – Resuscitation after ventricular fibrillation (RES)
Via a pacemaker lead, ventricular fibrillation (VF) was
induced by applying an alternating current (50 Hz). After
VF sustained for 5 min, resuscitation was begun by
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manual external chest compression at 80 min− 1, a single
bolus of 15 mg kg− 1 adrenaline and biphasic defibrilla-
tion (200 J, Responder 2000; General Electric, Fairfield,
CT, USA). Pigs (total n = 16) were assigned in a se-
quential 1:1 fashion to either normothermia (NT,
n = 8, 38.0 °C) or MH (n = 8, 33.0 °C) as shown in
Fig. 1 a. After 10 min past ROSC (return of spon-
taneous circulation), additional volume was given at
either room temperature to normothermic animals
or pre-cooled at 4 °C to cooled animals, consisting
of 16 ml kg− 1 crystalloid solution and 8 ml kg− 1
hydroxyethyl starch (Voluven 6% 130/0.4; Fresenius,
Austria) due to a substantial intravasal fluid loss.
No further inotropes were given after ROSC [21].
For the following data analysis, the timepoints base-
line and 6 h after return of spontaneous circulation
were used.
Group 2 – Myocardial infarction after coronary
microembolisation (CME)
Through repetitive slow (1min) injections of 500,000
polystyrene microspheres (45 μm) into the proximal left
circumflex coronary artery, myocardial infarction was
induced. The injections were continued until cardiac
power output was reduced by more than 40%. Three pigs
developed sustained ventricular fibrillation during the in-
jections and were excluded from the following analysis.
The remaining animals (total n = 16) were assigned in a
sequential 1:1 fashion to either NT (n = 8, 38.0 °C) or MH
(n = 8, 33.0 °C) as shown in Fig. 1a [22]. We used baseline
and 6 h after CME as timepoints for the data analysis.
Group 3 – Endotoxemia after LPS-infusion (LPS)
Following a Lipopolysaccharide (LPS)-infusion of 4 h,
pigs (total n = 13) were monitored for another 4 h,
Fig. 1 Experimental protocols: a Includes group 1–2 which are described as follows: group 1: resuscitation after ventricular fibrillation (RES, total
n = 16), group 2: myocardial infarction by coronary microembolisation (CME, total n = 16); b group 3: endotoxemia by LPS-infusion (LPS, total n =
13); c group 4: sevoflurane-induced myocardial depression (SEVO, total n = 5); d group 5: Temperature modulation from hyperthermia to mild
hypothermia vs dobutamine (DOB, total n = 9)
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resulting in a total of 8 h [23]. Assignment to either NT
(n = 7, 38.0 °C) or MH (n = 6, 33.0 °C) in a sequential 1:1
fashion started with the beginning of LPS-infusion (Fig.
1b). With the onset of LPS-infusion cooling was started
simultaneously in MH by the intravascular device and
infusion of pre-cooled (4 °C) instead of a crystalloid solu-
tion at room temperature (10 ml kg− 1 h− 1 in both
groups). When MAP fell below 55mmHg during LPS-
infusion, animals received up to four additional boluses
of 500 ml crystalloid infusion, of which the last two were
enriched with 1 μg kg− 1 epinephrine. When SaO2 (arter-
ial oxygen saturation) fell below 90%, FiO2 was increased
to 1.0 and the I: E ratio was changed to 1:1. When peak
respiratory pressure reached 35 mmHg, endotracheal
tube suction was performed, plus the tidal volume was
reduced to 8 ml kg− 1 with a compensatory increase in
respiration rate. For the following data analysis time-
points baseline and 8 h after onset of LPS infusion were
used.
Group 4 – Sevoflurane-induced myocardial depression
(SEVO)
After baseline measurements at NT (n = 5, 38.0 °C), the
continuous administration of sevoflurane was elevated from
a baseline of 1.0–2.0 to 4 Vol%. Subsequently, the continu-
ous administration of sevoflurane was reduced to baseline
values, and animals were cooled to MH (33.0 °C). After new
baseline measurements in the same animals at MH, the
continuous administration of sevoflurane was elevated from
1.0–2.0 to 3 Vol%. The Vol% of sevoflurane to induce car-
diac depression during NT and MH was established in a
series of pilot experiments. The sevoflurane dose was ti-
trated aiming at an approximate 50% reduction of LV dP/
dtmax. A lower Vol% of sevoflurane was needed to induce
the same magnitude of depression of contractile function
during MH, probably due to different pharmacokinetics of
the anesthetics at lower body temperatures, as previously
reported [28–32]. The abovementioned timepoints (base-
line at NT, 4 Vol% sevoflurane, baseline at MH and 3 Vol%
sevoflurane) were considered for data analysis (Fig. 1c).
Group 5 – Temperature modulation from hyperthermia to
mild hypothermia vs dobutamine (DOB)
A patient warming system (Bair Hugger, Warmtouch
Series 500/OR, 3M, Germany) with warming cover was
used to increase and maintain the animals (total n = 9)
body temperature at 40.5 °C (hyperthermia, HT). Only
animals in this group were subsequently cooled from
HT to NT and MH; at each temperature step baseline
measurements were followed by a dobutamine-stress
protocol until the steady state LV dP/dtmax was doubled
(Fig. 1d) [24]. The dose of dobutamine necessary to
double LV dP/dtmax decreased along with temperature
from 2.1 ± 0.1 μg kg− 1 min− 1 (hyperthermia) to 1.8 ±
0.1 μg kg− 1 min− 1 (normothermia) and further to 1.5 ±
0.1 μg kg− 1 min− 1 (mild hypothermia). Baseline measure-
ments at each temperature step and the corresponding
measurements during dobutamine infusion were consid-
ered for data analysis.
Data processing and statistical analyses
Details on data analysis have been described before [25].
Pressure-volume data and time intervals were analysed off-
line by CircLab Software (custom made by P. Steendijk).
End-diastole was defined as the time-point of zero crossing
of LV dP/dt before its rapid upstroke. End-systole was de-
fined as the time point of maximum pressure/volume ratio.
CPO (W), LV SWmin− 1 (W), LV EF, RPP and TP were cal-
culated by using the following equations:
– CPO (W) =MAP x CO/451 [12]
– LV SW min− 1 (W) = [(LV SW x HR)/60] ×
0.000133322
– LV EF (%) = Stroke volume (SV)/End-diastolic
volume (EDV)
– RPP (mmHgmin− 1) = HR x LVPmax
– TP (mmHg2 min− 1 s− 1) = RPP x LV dP/dtmax
All data are presented as mean ± standard deviation (SD).
The correlations between LV SW and LV SW min− 1 with
CPO, LV EF, RPP, TP, LVPmax and LV dP/dtmax were
assessed by linear regression analysis. The assumption of
normality of residuals was checked by the Kolmogorov-
Smirnov test as well as graphically by a probability plot. Data
between groups before and after cardiac insult at different
temperatures were analysed by two-way ANOVA (groups
1–3). A one-way ANOVA for repeated measurements was
used to compare data within one group (group 4). Steady
state data at different temperatures, before and during dobu-
tamine infusion, were compared by two-way ANOVA for
repeated measurements (group 5). Post-hoc testing was per-
formed by Tukey’s test. Normality was demonstrated by the
Shapiro-Wilks test or by visual inspection of normal prob-
ability plots. Nonnormally distributed variables were exam-
ined either by Kruskal-Wallis- or Friedman-Test. A p-value
< 0.05 was considered significant. For statistical calculations,
we used the software Sigmastat (Version 4.0, Systat Soft-
ware, Inc) and SPSS (Version 23.0, IBM, Armonk, NY).
Results
Systemic hemodynamics
Systemic hemodynamics from the experimental protocols
are summarized in Table 1. CO, LV SW min− 1 and CPO
spanned over a wide range of values, with the following
means (ranges): CO 5.7 Lmin− 1 (8.2 Lmin− 1), CPO 0.94
W (1.75W) and LV SW min− 1 0.99W (1.88W).
During mild hypothermia, heart rate decreased (p < 0.05)
in all animals and was significantly lower at MH than
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during normothermia or hyperthermia after each interven-
tion. Dobutamine infusion increased heart rate at each
temperature step.
Mean aortic pressure decreased with all interventions
and was more preserved during MH after myocardial in-
farction (p < 0.05).
In group 5 (DOB), CO and CPO decreased with
cooling from hyperthermia to normothermia to MH
and were increased by dobutamine at each
temperature step (Table 1). In groups 1–4, CO was
per se significantly lower during MH than during NT.
CPO decreased significantly with the interventions in
groups 1–4, but there was no significant difference
between NT and MH.
Systemic vascular resistance increased with cooling from
hyperthermia to MH and was decreased by dobutamine at
each temperature step. Except for sevoflurane-induced myo-
cardial depression, SVR was significantly higher during MH
after each intervention.
Cardiac power output and other parameters of cardiac
function as indices of left ventricular stroke work
CPO showed the best correlation with LV SWmin− 1 (Fig. 2;
r2 = 0.89; p < 0.001). LV EF did not correlate at all, neither
Table 1 Systemic hemodynamics
Hemodynamic Parameter Temp. Timepoint RES CME LPS SEVO Dob
HR HT Baseline 98 ± 12.8
(1 min− 1) After Intervention 122 ± 10.1c
NT Baseline 89 ± 10.6 89 ± 11.8 97 ± 10 90 ± 14.7 89 ± 13.2
After Intervention 84 ± 13.2 101 ± 18.5* 128 ± 17.4* 79 ± 9.6* 114 ± 10.2a, c
MH Baseline 86 ± 16.7 88 ± 10.8 98 ± 11.3 70 ± 10.1 65 ± 8a, b
After Intervention 59 ± 10.7*† 67 ± 11.4*† 79 ± 11.6*† 60 ± 5.9* 83 ± 11.2a, b, c
MAP HT Baseline 74 ± 8.4
(mmHg) After Intervention 77 ± 12.3
NT Baseline 92 ± 11.7 104 ± 17.3 86 ± 4.6 75 ± 7.1 68 ± 8
After Intervention 64 ± 8.2* 54 ± 13* 53 ± 10.6* 44 ± 4.9* 71 ± 11.8
MH Baseline 90 ± 8.7 107 ± 10.3 85 ± 5.9 67 ± 7.7 65 ± 7.7a
After Intervention 73 ± 15.4* 69 ± 6.7*† 58 ± 2.9* 42 ± 3.3* 69 ± 6.5a
CO HT Baseline 6.7 ± 0.9
(L min−1) After Intervention 8.4 ± 1c
NT Baseline 5.7 ± 1.2 6.2 ± 0.9 6.8 ± 0.5 6.7 ± 0.6 6.1 ± 1
After Intervention 4.8 ± 1.1 3.5 ± 0.7* 6.6 ± 1.3 5.0 ± 0,8* 7.8 ± 1.1c
MH Baseline 5.4 ± 1.3 6.5 ± 0.9 6.2 ± 0.8 4.9 ± 0.6 4.4 ± 0.6 a, b
After Intervention 3.5 ± 0.7*† 3.2 ± 0.5* 4.5 ± 1.22*† 4.4 ± 0.6 6.0 ± 0.85a, b, c
SVR HT Baseline 842 ± 152
(dyne.sec cm−5) After Intervention 717 ± 170c
NT Baseline 1238 ± 401 1292 ± 345 931 ± 76 848 ± 97 856 ± 171
After Intervention 915 ± 219 1089 ± 256 531 ± 83* 620 ± 117* 703 ± 128c
MH Baseline 1252 ± 310 1260 ± 153 1018 ± 139 1030 ± 137 1154 ± 202a, b
After Intervention 1470 ± 384† 1618 ± 252*† 884 ± 206† 675 ± 183* 880 ± 88a, b, c
CPO HT Baseline 1.10 ± 0.2
(W) After Intervention 1.40 ± 0.3c
NT Baseline 1.14 ± 0.2 1.43 ± 0.3 1.29 ± 0.1 1.12 ± 0.2 0.90 ± 0.2
After Intervention 0.69 ± 0.24* 0.42 ± 0.2* 0.80 ± 0.3* 0.48 ± 0.1* 1.20 ± 0.3a, c
MH Baseline 1.09 ± 0.3 1.55 ± 0.3 1.17 ± 0.2 0.72 ± 0.1 0.60 ± 0.1a, b
After Intervention 0.58 ± 0.2* 0.49 ± 0.1* 0.58 ± 0.2* 0.40 ± 0.0* 0.90 ± 0.2a, b, c
All values are presented as mean ± standard deviation (SD). Temp. Temperature, HT Hyperthermia, NT Normothermia, MH Mild hypothermia, RES Resuscitation after
ventricular fibrillation, CME Coronary microembolisation, LPS Endotoxemia by Lipopolysaccharide (LPS)-infusion, SEVO Sevoflurane-induced myocardial depression,
Dob Temperature modulation from hyperthermia to mild hypothermia vs. dobutamine (intervention) at each temperature step, HR Heart rate, MAP Mean aortic
pressure, CO Cardiac Output, SVR Systemic vascular resistance, CPO Cardiac Power Output
*p < 0.05 vs baseline; †p < 0.05 vs NT; ap < 0.05 vs hyperthermia; bp < 0.05 vs normothermia; cp < 0.05 vs baseline at each temperature step
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with LV SW (Fig. 3a; r2 = 0.02; p = 0.059) nor with LV SW
min− 1 (Fig. 3b; r2 = 0.01; p = 0.259). Other common param-
eters of cardiac function showed a statistically significant
but moderate correlation. RPP (Fig. 4a; r2 = 0.67; p < 0.001)
did correlate better than TP (Fig. 4b; r2 = 0.54; p < 0.001)
with LV SW min− 1. LVPmax showed a similar correlation
with LV SW (Fig. 5a; r2 = 0.55; p < 0.001), but correlated
worse with LV SW min− 1 (Fig. 5b; r2 = 0.47; p < 0.001). LV
dP/dtmax showed the worst correlation with both LV SW
(Fig. 5c; r2 = 0.23; p < 0.001) and LV SW min− 1 (Fig. 5d;
r2 = 0.28; p < 0.001). An additional file shows the correla-
tions between CPO and LV SW min− 1 of each individual
experimental group (Additional file 1).
Discussion
Here, we demonstrate that Cardiac Power Output accurately
reflects left ventricular stroke work per minute over a wide
range of inotropic states. Data were collected from experi-
mental studies of the hemodynamic impact of mild
hypothermia on acute heart failure models, such as 1) resus-
citation after ventricular fibrillation, 2) coronary no-reflow
infarction, 3) endotoxemia by LPS-infusion, 4) sevoflurane-
induced myocardial depression and 5) beta-adrenergic
stimulation via dobutamine infusion at different core-body
temperatures. We therefore investigated conditions ranging
from hypo- to hypercontractile LV function. CPO showed a
high positive correlation over the whole range of inotropic
states with LV SW min− 1, making it a valid parameter to
monitor inotropic interventions in the ICU setting.
Cardiac power output and left ventricular stroke work
The correlation between CPO, as measured by pulmon-
ary artery catheterization (PAC) and invasive arterial
pressure, and LV SW min− 1 measured via the invasive
gold-standard (conductance method) has never been
tested so far. Since pressure-volume analysis remains a
time-consuming, complex and highly invasive measure-
ment requiring additional equipment and expertise, the
concept of deriving similar information by assessing
CPO instead of LV SW is therefore quite attractive for
the clinical practice. Being assessed as the product of
cardiac output and mean aortic pressure and therefore
combining the heart’s ability to create both pressure and
flow, CPO describes the function of the heart as a hy-
draulic pump [13]. More precisely, hydraulic power in
general consists of two components. The power
expended to generate a steady (or non-pulsatile) flow is
described as the mean external power, which is assessed
as the product of mean arterial pressure and cardiac out-
put. The energy used in producing the pulsatile compo-
nent of flow and pressure is described as pulsatile
power. The sum of both mean and pulsatile power
results in the total external hydraulic power generated
by the ventricle [33]. Hence, CPO is a measure of mean
power, whereas LV SW is a measure of total energy
imparted to the vasculature system including pulsatile
power being assessed on a beat to beat basis. Under
physiological conditions, the fraction of pulsatile power
is about 10% of the total power generated by the left
Fig. 2 Cardiac Power Output (CPO) accurately reflects Left ventricular stroke work per minute (LV SW min− 1) over a wide range of inotropic
states. Any rise or fall of LV SW min− 1 corresponds to an equivalent change of CPO
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ventricle, while it rises with arterial hypertension, de-
creased distensibility of the proximal arteries and
increases in heart rate [34–36]. In the pulmonary cir-
culation, pulsatile power can make up to 30% of
total power [33, 37]. The ratio between pulsatile
power and mean power can be regarded as a meas-
ure of the efficiency of ventricular-arterial coupling,
while an increase of the pulsatile fraction indicates
a decrease in efficiency [35]. Although CPO does
not include information of pulsatile power, we could
show here for the first time a strong correlation to
LV SW min− 1 under various inotropic states during
acute heart failure. Of note, none of the experi-
ments included LV output tract (LVOT) obstruction
or aortic valve obstruction as well as severe stiffness
of the aorta, which in turn would have increased LV
SW min− 1 without changing CPO.
As abovementioned, CPO was shown to be the best
predictor of intrahospital mortality in patients with car-
diogenic shock [12]. Furthermore, it allows an exact
hemodynamic characterization of patients with acute
congestive heart failure by plotting CPO with SVR [38]
and it was shown to be the only parameter, when mea-
sured at baseline, with a significant prediction of
Fig. 3 Left ventricular ejection fraction (LV EF) did not correlate with (a) Left ventricular stroke work per beat (LV SW) nor with (b) Left ventricular
stroke work per minute (LV SW min− 1)
Fig. 4 Both (a) Rate Pressure Product (RPP) and (b) Triple Product (TP) correlated moderately with Left ventricular stroke work per minute (LV
SW min− 1)
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recurring severe acute heart failure (manifested as frank
pulmonary edema) within 24 h from hospitalization in
the ICU setting [39]. However, the role of CPO has not
been yet fully integrated into the clinical ICU routine, in
part due to a lack of data supporting the use of PAC in
patients with advanced heart failure. In a meta-analysis
investigating 13 randomized controlled trials (RCT) on
the impact of PAC on survival, Shah et al. [4] argued
that the neutral effects of PAC might be based on un-
clear hemodynamic goals in combination with a lack of
effective treatment strategies driven by the obtained
hemodynamic measurements [2, 4]. We suggest here
that CPO obtained via PAC is an excellent parameter to
monitor cardiac performance in experimental conditions
resembling critically-ill patients. Furthermore, recent
data show the feasibility of a minimally invasive assess-
ment of CPO and cardiac power integral [40–43],
opening new scenarios of CPO-based monitoring of crit-
ical patients without the need for PAC.
Left ventricular ejection fraction
We could clearly show that LV EF does not reflect exter-
nal cardiac work over a wide range of experimental ino-
tropic states representative for patients during acute
heart failure. In clinical practice, LV EF plays a major
role in the diagnosis and treatment of heart failure, as a
surrogate marker of cardiac remodelling [44] and reverse
remodelling [45] or as a general predictor of outcome in
heart failure with reduced LV EF [46, 47]. Nevertheless,
our data imply that LV EF is not accurate enough in
mirroring the function of the heart as a hydraulic
pump under various conditions of acute heart failure
and should be preferably interpreted within the
hemodynamic context.
Fig. 5 LV maximum pressure (LVPmax) showed a better correlation with both (a) Left ventricular stroke work per beat and (b) Left ventricular
stroke work per minute (LV SW min− 1) than maximum rate of rise of LVP (LV dP/dTmax, c and d)
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LV pressure and pressure-derived indices of cardiac
workload
The rate pressure product and the triple product are
both clinical indices of myocardial oxygen consumption
and therefore regarded as indirect measures of cardiac
work [48–52]. Thus, we used these parameters as surro-
gates for LV SW min− 1. In our findings, we confirm a
correlation between both RPP and TP with LV SW min−
1, with RPP having a better correlation than TP. The
worse correlation of TP with LV SW min− 1 could be ex-
plained by integrating LV dP/dtmax into the calculation
which is known to be a preload, afterload and heart rate
dependent measure of cardiac contractility [44, 53–55].
Also, LV dP/dtmax itself correlated worst with LV SW
and LV SW min− 1.
Interestingly, LVPmax alone correlated as good as the
TP with LV SW, emphasizing the potential role of esti-
mating LV pressure as a measure of the actual work
done by the left ventricle in specific subpopulations of
cardiogenic shock patients, i.e. under left ventricular
assistance.
Limitations
The main limitation is the retrospective design of the
study, meaning that the analysed data were not always
part of the major outcome of the original studies.
However, the quality of the original tracings has been
reviewed by 2 independent investigators. Specific limi-
tations related to the experimental setup from which
these data were derived have been described earlier
[21–24]. Another limitation of the study is related to
the fact that animals were investigated under general
anaesthesia, in order to minimize the animals’ distress
and to obtain stable hemodynamic conditions. Never-
theless, we believe the data to be representative
enough for the translation to a clinical ICU setting.
Furthermore, the study did not include experimental
models of LVOT obstruction or increased stiffness of
the aorta for modelling of patients with aortic sten-
osis or severe arteriosclerosis.
Conclusions
CPO is an excellent parameter of external cardiac work
over a wide range of inotropic states, while clinically
established indices to describe cardiac function, such as
LV ejection fraction, rate-pressure product and triple
product perform poorly.
These data further support the use of CPO to monitor
cardiac workload as well as the effect of inotropic inter-
ventions in critically ill patients in the ICU setting. Clin-
ical studies will address the impact of CPO on
improving patients’ survival.
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